BTAI (STOCKS)
BioXcel Therapeutics, Inc. Common Stock
$1.040000
-0.020000 (-1.89%)
Prev close: $1.060000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Vimal D. Mehta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $27.84M
- Employees
- 37
- P/E (TTM)
- -0.15
- P/B (TTM)
- -0.25
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.58 | $-0.77 | +0.1850 | +24.18% |
|
Sep 2025 (Q3)
|
$-2.18 | $-1.20 | -0.9789 | -81.50% |
|
Jun 2025 (Q2)
|
$-2.45 | $-1.89 | -0.5569 | -29.42% |
|
Mar 2025 (Q1)
|
$-1.50 | $-6.79 | +5.2898 | +77.91% |
Financial Statements
| Revenues | $642.00K |
| Benefits Costs and Expenses | $70.54M |
| Cost Of Revenue | $164.00K |
| Costs And Expenses | $51.10M |
| Gross Profit | $478.00K |
| Operating Expenses | $50.94M |
| Selling, General, and Administrative Expenses | $20.49M |
| Research and Development | $30.25M |
| Other Operating Expenses | $194.00K |
| Operating Income/Loss | -$50.46M |
| Income/Loss From Continuing Operations After Tax | -$69.90M |
| Income/Loss From Continuing Operations Before Tax | -$69.90M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$69.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$69.90M |
| Net Income/Loss Available To Common Stockholders, Basic | -$69.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.73 |
| Diluted Earnings Per Share | -$5.73 |
| Basic Average Shares | 12,208,000 |
| Diluted Average Shares | 12,208,000 |
| Assets | $44.92M |
| Current Assets | $44.69M |
| Accounts Receivable | $233.00K |
| Inventory | $722.00K |
| Other Current Assets | $43.73M |
| Noncurrent Assets | $231.00K |
| Fixed Assets | $175.00K |
| Other Non-current Assets | $56.00K |
| Liabilities | $140.38M |
| Current Liabilities | $53.93M |
| Accounts Payable | $14.70M |
| Wages | $34.00K |
| Other Current Liabilities | $39.19M |
| Noncurrent Liabilities | $86.45M |
| Long-term Debt | $109.59M |
| Equity | -$95.46M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$95.46M |
| Liabilities And Equity | $44.92M |
| Net Cash Flow From Operating Activities | -$57.62M |
| Net Cash Flow From Operating Activities, Continuing | -$57.62M |
| Net Cash Flow From Investing Activities | $1.10M |
| Net Cash Flow From Investing Activities, Continuing | $1.10M |
| Net Cash Flow From Financing Activities | $56.52M |
| Net Cash Flow From Financing Activities, Continuing | $56.52M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$69.90M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$69.90M |
| Other Comprehensive Income/Loss | $0.00 |